Pharmacological investigations to date have yielded evidence that KOR agonists may be useful as treatments for chronic pain, pruritis, multiple sclerosis, AD, immune modulated diseases, gastrointestional diseases, cancer, hypoxia and ischemia and various other disorders. The gene discussed is OPRK1; the disease is cancer.